

Biotin-Ligand Complexes with Streptavidin Quantum Dots for *in vivo* Cell Labeling of Membrane Receptors

Diane S. Lidke¹, Peter Nagy², Thomas M. Jovin¹, Donna J. Arndt-Jovin^{1*}

¹Department of Molecular Biology, Max Planck Institute for Biophysical Chemistry, 37077 Goettingen, Germany

²Current address: Department of Biophysics and Cell Biology, Medical and Health Science Center University of Debrecen, 4012 Debrecen Hungary

Running title: Ligand-Quantum Dot complexes

*** To whom correspondence should be addressed.**

E-mail: djovin@gwdg.de

Phone: 49(0)551-2011393 **FAX:** 49(0)551-2011467

Submitted for:

“Quantum Dots in Biology”, ed. M. Bruchez (Humana Press, Totowa, NJ, 2005)

Summary

The unique fluorescence properties of quantum dots (QDs), particularly high brightness and photostability, make them ideal probes for tracking proteins in live cells using real-time visualization. We have shown that QDs conjugated to Epidermal Growth Factor (EGF) act as functional ligands for their receptor, erbB1. Here, we describe protocols for (a) conjugation of streptavidin-QDs to biotinylated ligand, (b) formation of ligand-QD-receptor complexes and (c) quantification of binding and internalization of receptor complex using both high-resolution fluorescence microscopy and flow cytometry.

Keywords: epidermal growth factor, EGF, epidermal growth factor receptor, EGFR, erbB1, endocytosis, biotin, streptavidin

1. Introduction

The erbB family of receptor tyrosine kinases (RTK) includes erbB1 (the classical epidermal growth factor receptor, EGFR), erbB2, erbB3 and erbB4 (1). Binding of EGF to the extracellular domain of erbB1 leads to auto- and transactivation of cytoplasmic protein kinase domains in response to the formation (3) or reorientation (4-6) of homo- and heteroassociated RTK monomers. This activation of the receptor initiates signaling cascades, which control a variety of cellular processes such as DNA replication and division (1,2). ErbB1 activation results in clathrin-mediated endocytosis via coated pits, covalent modification of the receptor, and endosomal trafficking resulting in both down-regulation through proteosomal degradation and recycling to the cell membrane. The proper function of erbB1 in the cell is critical, given that overexpression or mutations of the erbB1 are implicated in many types of cancer (1,7).

We have shown that QDs conjugated to EGF act as functional ligands for erbB1, and that their unique fluorescence properties provide the means for prolonged real-time visualization of the multiple steps in signaling mechanisms in living cells (8). In this chapter we outline procedures for binding biotinylated ligands to commercial streptavidin conjugated quantum dots, for specific labeling of growth factor receptors with these ligands and for quantitative measurements of the receptor complexes by both fluorescence microscopy and flow cytometry.

2. Materials

1. Phosphate buffered saline (PBS): 137 mM NaCl, 2.7 mM KCl, 7.9 mM Na₂HPO₄, 1.5 mM KH₂PO₄, pH 7.3. Autoclave before use and store at room temperature. PBS/BSA: add 0.1% BSA just before use.
2. Tyrode's buffer without glucose: 135 mM NaCl, 10 mM KCl, 0.4 mM MgCl₂, 1 mM CaCl₂, 10 mM HEPES, pH 7.2. Autoclave before use and store at room temperature. Tyrode's plus: add 20 mM glucose and 0.1% BSA just before use.
3. Streptavidin conjugated Quantum Dots from Quantum Dot Corporation (Hayward, CA, www.qdots.com). Hereafter called SA_vQD.
4. LabTek 8-well or 2-well coverslip chambers from Nunc.
5. Coverslips, acid washed and sterilized.
6. Cell culture medium appropriate for the particular cell line. Various commercial vendors.
7. Emission filters for specific QD emission wavelengths, 20 nm FWHM Chroma (Brattleboro, VT).
8. Biotinylated-EGF and EGF from Molecular Probes (Invitrogen, www.probes.com).

9. Paraformaldehyde (PFA) fixative. Paraformaldehyde, analytical grade. Freshly prepared 4% solution in PBS. A 40% solution can be prepared and kept in small aliquots at -20°C . Thaw at 50°C and immediately dilute in PBS before use.
10. Tris-saline buffer: 125 mM NaCl, 25 mM Tris-HCl, pH 7.3.
11. Trypsin solution for releasing adherent cells from their substrates: sterile solution of 0.5 mg/ml trypsin in PBS containing 1 mM EDTA.
12. Acid wash buffer: 0.5 M NaCl, 0.1 M Glycine-HCl, pH 2.5.

3. Methods

3.1 Protocols for making biotin-ligand linked streptavidin-QDs (SAvQD)

3.1.1 Ratio of biotinylated ligand to QDots

The present formulation of the QDs from Quantum Dot Corporation includes a polyethylene glycol 2000 (PEG) outer layer to which 5-10 streptavidin molecules per QD are covalently linked. This allows the stoichiometry of the ligand-QD complex to be varied. It is preferable to use monovalent biotinylated ligands where the biotin is conjugated to a single known residue or position. In this way the properties of the ligand-QD complex can be better controlled and standardized and potential cross-linking of the QDs via the ligand is avoided. By mixing SAvQDs, biotinylated ligand and free biotin at different molar ratios, one can create QDs with different numbers of attached ligands. We assume a Poisson distribution. To create primarily monovalent biotin conjugates mix a 10-fold molar excess of SAvQDs with the biotinylated ligand.

3.1.2 Pre-formed complexes

1. Dilute SAvQD to 20 nM in PBS/BSA.
2. Dilute biotinylated ligand to the appropriate desired molarity in PBS/BSA.
3. Add SAvQDs to ligand and mix with a micropipette.
4. Incubate at 4 °C for at least 30 min with gentle agitation or rotation. (See **Note 1**).

3.1.3 Purification of ligand-QD conjugates

After the ligand-QD complex is formed, unbound ligands that are smaller than the QDs can be removed from the conjugate by passing the QDs through a size exclusion column. For SAvQDs described above, Sephadex G-25 medium grade gel filtration is recommended; the SAvQDs will elute in the void volume. Use a 1: 20 ratio of sample to column volume for good separation.

Spin columns can be used for sample volumes of 50 μ l or less.

1. Swell and pour the Sephadex according to the manufacturer's instructions.
2. Equilibrate the column in PBS by washing with at least 3 column volumes.
3. Allow the buffer to just enter the top of the gel bed before adding the sample. Avoid air bubbles.
4. Add the sample to the top of the gel bed, allow the sample to enter the gel and add PBS to elute the sample.
5. Collect the fractions containing the QDs.

3.2 *In vivo, in situ* labeling of cells with ligand-QD conjugates for fluorescence microscopic imaging

3.2.1 Plating cells

Coverslips and coverslip chambers

Logarithmically growing cells are replated in complete culture medium at the appropriate densities one or two days prior to the experiment. In the case of experiments with growth factor receptors, the cells are serum-starved for 16 - 24 h prior to the experiment to reduce signaling induced by the serum in the medium.

3.2.2 Labeling cell surface receptors with preformed ligand-QD complex

1. Wash cells once with Tyrode's plus and maintain in this buffer for the experiment.
2. Place the coverslip chamber on the microscope stage and equilibrate to the desired temperature.
3. Dilute the ligand-SAvQD complex (in this case EGF-QD) to twice the final concentration in Tyrode's plus. (See **Note 2**.)
4. Add an equal volume of EGF-QD in Tyrode's plus to the cells in the well under observation to a final concentration of 5 - 200 pM.
5. Start imaging.

3.2.3 Labeling cell surface receptors in a two-step procedure

In some situations the preformed complex may not be functional or the system may not respond properly with the preformed complex due to (a) steric hindrance by the SAvQD during ligand binding or (b) SAvQD inhibition of a conformational change of the ligand required for binding. In addition, ligands with multiple biotins can cause aggregation of SAvQDs. Thus, if

one does not see binding with the preformed complex or observes aggregation of SAvQDs in the one-step protocol, the following two-step protocol may be useful. We have successfully used this procedure with both the EGF and the transferrin receptors (8,9).

1. Wash cells once with ice cold Tyrode's plus and keep in this buffer for the experiment.
Put cells on ice.
2. Incubate cells with biotinylated-ligand (in this case 1 nM biotin-EGF, see **Note 3**) for 5-10 min.
3. Wash with ice cold Tyrode's plus several times.
4. Add cold 200 pM SAvQD for 5-15 min.
5. Wash the cells several times with cold Tyrode's plus.
6. Place cells on the microscope stage with appropriate temperature control and image.
7. For snapshots of the behavior of the ligand-QD complex over time, incubate coverslips at the appropriate temperatures and times and fix in 4% paraformaldehyde for 15 min on ice to prevent redistribution of the QDs. After fixation, wash the coverslips with Tris-saline buffer for 10 min several times and mount in PBS for microscopy.

3.2.4 *In vivo* visualization and quantitation of ligand-QD binding by fluorescence confocal microscopy

Binding plot for ligand-QD to cells expressing a GFP membrane protein (may be the ligand-binding protein or another membrane protein simply used as a marker).

1. Grow cells in 8-well LabTek chambers as described above.

2. Wash cells once with Tyrode's plus and keep in 200-250 μL of Tyrode's plus for imaging.
3. Begin acquisition of a time series with single or multiple focal planes.
 - a. Typically, a 63 \times or 40 \times 1.2 NA water immersion objective is recommended. Simultaneous excitation of GFP and QD605 can be achieved at 488 nm. An imaging system with two detectors, e.g. Zeiss LSM510-META, allows the simultaneous collection of GFP and QD signals with appropriate filters (in this case, 520/20 bandpass and 585 longpass, respectively).
4. After several time points are acquired, add the pre-formed EGF-QD complexes to the buffer (1:1 dilution) without disrupting the time series.
5. Analysis (8)
 - a. Background subtraction from both channels is performed.
 - b. The membrane region of the cell is segmented by a global threshold in the green channel and the mask is dilated according to a pixel width corresponding to the membrane circumference.
 - c. The average QD intensity (from the red channel) in the membrane mask is plotted over time (See Figure 1).

3.2.5 Two-color QD "chase" experiment

Multicolor EGF-QDs may be used to track endocytosis of the receptor-ligand complex and to follow subsequent steps in time. Two different colors of ligand-QDs are delivered sequentially. (An example of this data may be found in a color image included only on the CD ROM copy of this chapter, Figure S1)

1. The day before the experiment, plate cells on coverslips if taking fixed cell time points or in Lab-Tek coverslip chambers for live cell imaging.
2. Prepare two batches of QD-ligand as above, with separated emission spectra, such as SAvQD525 and SAvQD605.
3. Wash the cells in Tyrode's plus buffer and keep in this buffer.
4. Incubate the cells in a non-saturating concentration (<200 pM in the case of EGF-QD) of the first QD-ligand (QD605) for 5 – 10 min at 37 °C while taking time-lapse images on a confocal microscope or incubate coverslips in a moist chamber for samples to subsequently fix.
5. Wash away excess QD-ligand by two changes of Tyrode's plus.
6. Incubate at 37 °C for at least 5 min to clear the membrane of ligand-QD (image *in vivo*).
7. Add 1 nM of ligand of another color, EGF-QD (QD525), and incubate at 37 °C for desired time *in vivo* with imaging or for desired fixed time points.
8. For fixed samples, wash coverslips in Tyrode's buffer and fix at 4 °C for 15 min in 4% PFA (see section 3.2.3).
9. Wash with cold Tris-saline several times.
10. Antibody staining for activated erbB1, endocytic markers or other cell components can be carried out at this point.
11. Mount coverslips onto a drop of PBS on a microscope slide, seal with nail polish. Image in fluorescence microscope using appropriate filters.

3.3 Quantitative measurement of EGF-QD binding and internalization using flow cytometry

Many properties of quantum dots, including their brightness and extreme photostability, make them very valuable for time-lapse fluorescence microscopy. However, a QD-labeled ligand or antibody is increased in size by 10-20 nm per bound QD. Therefore, carefully planned control experiments are necessary to establish that the QD does not interfere with the normal biological function of the ligand or antibody. Flow cytometry is an indispensable method for quantitation of binding and internalization data with high statistical precision. The following protocol can be used to show specific and saturable binding of EGF-QD to erbB1 on the cell surface, and demonstrate its uncompromised biological activity by monitoring internalization of the acceptor-ligand complex.

3.3.1 EGF-QD specifically binds to a saturable binding site in the membrane of erbB1-expressing cells

1. Prepare preformed EGF-QD at a ratio of 1:1 as described in section 3.1.2 - 3.1.3.
2. Trypsinize A431 cells and resuspended in PBS/BSA at a density of $5 \cdot 10^6/\text{mL}$, and store on ice (see **Note 4**).
3. Prepare a 2-fold dilution series of EGF-QDs. 1000 μL of the highest concentration of EGF-QD (100 nM) in PBS/BSA in a flow cytometry tube (see **Note 5**). Thorough mixing is very important. The tubes are kept on ice during the entire labeling procedure. 500 μL is pipetted from this solution to another tube to which 500 μL of PBS/BSA is added yielding the second highest concentration (50 nM) of EGF-QD. This procedure is

repeated until the lowest concentration is reached. The result is a dilution series of tubes filled with 500 μL of different concentrations of the ligand on ice (see **Note 6**).

4. Add 20 μL of the cell suspension to each ligand solution and mix thoroughly (see **Note 7**). Incubate the cells on ice for 60 min with regular mixing.
5. Measure the samples on a flow cytometer without washing (see **Note 8**). An unlabeled cell sample is also included in the measurement, the fluorescence intensity of which is subtracted from the mean fluorescence intensities of each sample. The corrected fluorescence intensities are plotted as a function of ligand concentration, and the characteristics of ligand binding are analyzed.

3.3.2 Binding of streptavidin-coated quantum dots to cells labeled with different molar ratios of EGF and biotin-EGF

Results of the previous experiments showed that EGF-QD binds to a saturable binding site on the surface of A431 cells. Strong evidence for specific binding is provided by competitive inhibition by another ligand. Activation of erbB1 requires the binding of two EGF molecules to a dimer of erbB1 receptor (3, 10). The relatively large size of quantum dots requires one to show unambiguously that the ligand-QD is functional. Furthermore, if erbB1 molecules are at high density on the cell surface of A431 cells, a bound quantum dot may sterically hinder binding to a neighboring receptor. To rule out size or steric hindrance by the QDs, we labeled cells with different molar ratios of EGF and biotinylated-EGF, followed by SAVQD and determined whether the fluorescence intensities of the samples were linearly proportional to the molar fraction of biotin-EGF. The higher the molar fraction of biotinylated-EGF, the higher the probability of finding two biotinylated-EGF molecules close to each other, e.g. binding to two

erbB1 proteins in a dimer. This would result in leveling off of the fluorescence intensity curve at high biotin-EGF concentrations. The fact that we found a strictly linear relationship implies that binding of streptavidin-coated quantum dots is not sterically limited (Fig. 2).

1. Trypsinize A431 cells and resuspend in PBS/BSA at a density of $2 \cdot 10^6$ /mL. Store on ice (see **Note 4**).
2. Prepare 100 nM stock solutions of biotin-EGF and EGF in PBS/BSA. Keep the solutions on ice.
3. Prepare a 20 nM stock solution of SA_vQD in PBS/BSA and store on ice.
4. Prepare a series of samples (total volume of each is 50 μ L) in which the molar ratio of biotin-EGF changes from 0 to 100 %, e.g. 0, 12.5, 25, 37.5, 50, 62.5, 75, 87.5, 100%). The total concentration of EGF (biotinylated+non-biotinylated) is 100 nM in each sample.
5. Add 50 μ L of cell suspension to each tube and mix thoroughly. Incubate the samples on ice for 30 min with regular shaking.
6. Layer 1 mL of fetal calf serum under the cell suspension and centrifuge the cells at 4 °C. Discard the supernatant.
7. Add 300 μ L of the 20 nM quantum dot solution to each pellet and incubate the samples on ice for 30 min with regular shaking (see **Note 9**).
8. Without washing, measure the sample intensities using a flow cytometer.

3.3.3 Quantitative measurement of EGF-QD internalization

Although microscopy experiments can measure the internalization of ligand-QD in a qualitative or semi-quantitative manner with subcellular resolution, flow cytometry is indispensable for obtaining a quantitative description of the process.

1. Couple Biotin-EGF to SAVQDs at a molar ratio of 6:1 as described in section 3.1.2.
2. Trypsinize A431 cells and resuspended at a density of 10^6 /mL in Tyrode's buffer plus.
3. Add 1 nM EGF-QD to the sample and incubate at 37 °C with regular shaking.
4. Take 600 μ L samples at 0, 5, 10, 20 and 30 min.
5. Add 5 mL of acid wash buffer to half of the sample, and incubate on ice for 5 min.
6. Wash with a large excess of PBS and resuspend cells in 300 μ L Tyrode's plus.
7. Measure the fluorescence intensities of the acid washed sample and the non-acid-treated sample by flow cytometry to obtain the fraction of internalized ligand. (See **Note 10**).

4. Notes

1. Thoroughly mix the SAVQDs and ligands by pipetting up and down several times. Mix in equal volumes so that the stoichiometry does not vary throughout the solution at the time of mixing.
2. Dilute the ligand-SAVQD complex from PBS into Tyrode's plus just before use since the SAVQDs aggregate with time in buffers containing divalent cations.
3. In performing similar experiments on another system than the EGFR, the researcher should adjust the concentration of ligand and incubation times according to the binding constant of the receptor or protein- ligand interaction.

4. The cell membrane is in a constant state of recycling. Antibodies and ligands typically induce the internalization of their receptor, and newly synthesized receptors continuously reach the plasma membrane by exocytosis. If cells are labeled at a temperature permissive to endo- and exocytosis, cells engulf EGF-QD receptors, and the freshly exocytosed receptors will also bind EGF-QD due to the continued presence of the label in the extracellular space. This results in a higher level of EGF-QD binding than what would be expected based on the original number of receptors on the cell surface, giving rise to binding that is difficult to saturate. Therefore, both the cell suspension and the ligand dilution series are kept on ice during the whole duration of the experiment, and all solutions are prepared in flow cytometry tubes to minimize the number of times a solution has to be transferred from one tube to another. Although flow cytometers are usually not thermostated, if the tubes are kept on ice until measurement, ligand internalization is minimized.

5. The amount of receptor-bound ligand is usually negligible compared to the total amount. However, if a high affinity ligand is investigated and the labeling volume is minimized, the decreased concentration of free ligand in the extracellular space (called ligand depletion) cannot be overlooked. E.g. if 10^5 cells expressing 10^6 receptors/cell are labeled in the presence of 10 nM ligand in a volume of 500 μL , the number of bound ligands is $10^5 \cdot 10^6 = 10^{11}$ assuming saturation. The total number of added ligands is $10 \cdot 10^{-9} \text{ mole/L} \cdot 500 \cdot 10^{-6} \text{ L} \cdot 6 \cdot 10^{23} \text{ 1/mole} = 3 \cdot 10^{12}$. In this case 33% of the total ligand amount is bound, severely distorting the calculations. As a rule of thumb 5% ligand depletion is usually

considered negligible. Beyond this limit either the real free ligand concentration has to be determined or corrections have to be introduced in the calculation, the details of which are beyond the scope of this chapter.

6. The ligand can also be depleted by binding to the wall of the labeling tube which can be minimized by carrying out the experiment in the presence of 0.1-0.5% (w/v) BSA. In addition, the same number of cells are labeled in identical volumes to ensure similar conditions (e.g. a constant number of total binding sites).

7. Dilution of the ligand after adding 20 μL cell suspension to 500 μL ligand solution is either neglected or can be corrected for in the following way: $c_{corr} = c_{orig} \cdot 500/520$, where c_{corr} and c_{orig} are the concentrations of the ligand in the diluted and undiluted solutions, respectively.

8. Ligand dissociation starts immediately when the concentration of ligand drops in the extracellular solution. Therefore, we suggest that samples not be washed before labeling. In the case of high affinity ligands saturating their binding site at a low concentration fluorescence of the extracellular ligands is negligible. In addition, flow cytometers are equipped with a constant background subtraction algorithm, reliably accounting for the contribution of extracellular fluorescence even in the case of low affinity ligands.

9. The number of erbB1 proteins in 10^5 labeled A431 cells is $10^5 \cdot 2 \cdot 10^6 = 2 \cdot 10^{11}$ corresponding to $2 \cdot 10^{11} / 6 \cdot 10^{23} / 300 \mu\text{L} = 1.1 \text{ nM}$ mean receptor concentration. The

concentration of QD was chosen to be 20 nM to ensure a ~20-fold excess of unbound QDs.

10. Since acid washing removes non-covalently-bound molecules from the cell surface, the fluorescence intensity of acid-washed samples will represent the internalized pool of QD-labeled ligands.

Acknowledgements

This work was funded by EU FP5 Grants QLRT-2000-02278 and QLG1-CT-2000-01260 awarded to T.M.J and the Max Planck Gesellschaft.

Figure Legends

Figure 1. Quantitation of EGF-QDs binding to Chinese Hamster Ovary cells expressing erbB1-eGFP. Plot shows the change in QD intensity inside the membrane mask over time. The binding of the EGF-QDs to the cell surface follows an exponential course.


Figure 2. Binding of SAvQDs to cells labeled with different molar ratios of biotinylated- and non-biotinylated-EGF

A431 cells were incubated in the presence of different molar ratios of biotin-EGF and EGF for 60 min followed by labeling with SAvQDs. The fluorescence intensity of the samples (empty circles) was measured using flow cytometry. The correlation coefficient of a linear fit to the data (straight line) was $R=0.99$. Originally published in (8).


5. References

1. Yarden, Y. & Sliwkowski, M.X. (2001) Untangling the ErbB signalling network. *Nat. Rev. Mol. Cell Biol.* **2**, 127-137
2. Jorissen, R.N. *et al.* (2003) Epidermal growth factor receptor: mechanisms of activation and signalling. *Exp. Cell Res.* **284**, 31-53
3. Schlessinger, J. (2002) Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. *Cell* **110**, 669-672
4. Gadella Jr., T.W.J. & Jovin, T.M. (1995) Oligomerization of epidermal growth factor receptors on A431 cells studied by time-resolved fluorescence imaging microscopy. A stereochemical model for tyrosine kinase receptor activation. *J. Cell Biol.* **129**, 1543-1558
5. Moriki, T., Maruyama, H. & Maruyama, I.N. (2001) Activation of preformed EGF receptor dimers by ligand-induced rotation of the transmembrane domain. *J. Mol. Biol.* **311**, 1011-1026
6. Sako, Y., Minoghchi, S. & Yanagida, T. (2000) Single-molecule imaging of EGFR signalling on the surface of living cells. *Nat. Cell Biol.* **2**, 168-172
7. Hynes, N.E., Horsch, K., Olayioye, M.A. & Badache, A. (2001) The ErbB receptor tyrosine family as signal integrators. *Endocr. Relat. Cancer* **8**, 151-159.
8. Lidke, D.S. *et al.* (2004) Quantum dot ligands provide new insights into erbB/HER receptor-mediated signal transduction. *Nat. Biotechnol.* **22**:198-203.

9. Grecco, H. *et al.* (2004) Ensemble and single particle photophysical properties (two-photon excitation, anisotropy, fret, lifetime, spectral conversion) of commercial quantum dots in solution and in live cells. *Micros. Res. Tech.* **65**, 169-179.
10. Mattoon, D., P. Klein, M.A. Lemmon, I. Lax, and J. Schlessinger. (2004) The tethered configuration of the EGF receptor extracellular domain exerts only a limited control of receptor function. *Proc. Nat. Acad. Sci. USA.* **101**:923-928.




Lidke et al. Figure 1



Lidke et al. Figure 2

QDots track endosomal compartments and vesicular fusion


Pulse chase experiments with two different QD-EGFs



QD605-EGF bound to ErbB1 (A431 cells), incubated RT for 3 min, washed, 5 min 37° C
- add QD525-EGF 8 min 37° C
Early endosomes red only, QD525-EGF predominantly external.



Washed and observed 20 min later at 37° C.
Several different classes of endosomes containing red only, green only or both QD colors (see inset).
Early, sorting and late endosomes are loaded.



2 hr later, although all vesicles show red and green signals, clear differences in QD populations are seen in the content of late endosomes and lysosomes.